Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1991 1
1992 2
1994 2
1996 3
1997 3
1998 2
1999 2
2000 3
2001 2
2002 3
2005 1
2006 1
2007 1
2008 2
2009 2
2010 3
2011 5
2012 9
2013 10
2014 13
2015 9
2016 14
2017 23
2018 17
2019 14
2020 15
2021 16
2022 12
2023 7
2024 7
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
Horinouchi H, Murakami H, Harada H, Sobue T, Kato T, Atagi S, Kozuki T, Tokito T, Oizumi S, Seike M, Ohashi K, Mio T, Sone T, Iwao C, Iwane T, Koto R, Tsuboi M. Horinouchi H, et al. Among authors: atagi s. Lung Cancer. 2025 Jan;199:108027. doi: 10.1016/j.lungcan.2024.108027. Epub 2024 Nov 14. Lung Cancer. 2025. PMID: 39708388 Free article.
Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01.
Yoshioka H, Ishida T, Atagi S, Tamiya A, Nishimura T, Iwamoto Y, Kanehara M, Kim YH, Korogi Y, Tomii K, Katakami N, Komuta K, Nishikawa M, Gemma A, Yamaki K, Kawahara M, Miyakoshi C, Mio T. Yoshioka H, et al. Among authors: atagi s. Clin Lung Cancer. 2025 Jan;26(1):1-8. doi: 10.1016/j.cllc.2024.09.004. Epub 2024 Oct 1. Clin Lung Cancer. 2025. PMID: 39482146 Clinical Trial.
Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.
Sakura K, Kuroyama M, Shintani Y, Funaki S, Atagi S, Kadota Y, Kuribayashi K, Kijima T, Nakano T, Nakajima T, Sasai M, Okumura M, Kaneda Y. Sakura K, et al. Among authors: atagi s. Cancer Immunol Immunother. 2024 Oct 3;73(12):243. doi: 10.1007/s00262-024-03815-1. Cancer Immunol Immunother. 2024. PMID: 39358654 Free PMC article. Clinical Trial.
Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study.
Tsuboi M, Murakami H, Harada H, Sobue T, Kato T, Atagi S, Tokito T, Mio T, Adachi H, Kozuki T, Sone T, Seike M, Toyooka S, Kitagawa H, Koto R, Yamazaki S, Horinouchi H. Tsuboi M, et al. Among authors: atagi s. Thorac Cancer. 2024 Jul;15(20):1541-1552. doi: 10.1111/1759-7714.15305. Epub 2024 May 29. Thorac Cancer. 2024. PMID: 38812106 Free PMC article.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, Atagi S, Kozuki T, Takeoka H, Chikamori K, Shinagawa N, Tanaka H, Horii E, Adrian S, Bruns R, Johne A, Paik PK, Sakai H. Morise M, et al. Among authors: atagi s. Cancer Sci. 2024 Apr;115(4):1296-1305. doi: 10.1111/cas.16107. Epub 2024 Feb 25. Cancer Sci. 2024. PMID: 38402853 Free PMC article. Clinical Trial.
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, Okami J, Sakakura N, Kubota K, Takamochi K, Atagi S, Tsuboi M, Oizumi S, Ikeda N, Ohde Y, Ntambwe I, Mahmood J, Cai J, Tanaka F. Mitsudomi T, et al. Among authors: atagi s. Cancer Sci. 2024 Feb;115(2):540-554. doi: 10.1111/cas.16030. Epub 2023 Dec 14. Cancer Sci. 2024. PMID: 38098261 Free PMC article. Clinical Trial.
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K. Nishio M, et al. Among authors: atagi s. Transl Lung Cancer Res. 2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13. Transl Lung Cancer Res. 2023. PMID: 37425411 Free PMC article.
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study.
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Itani H, Endo T, Saito AM, Shibayama T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: atagi s. JTO Clin Res Rep. 2023 Apr 6;4(6):100514. doi: 10.1016/j.jtocrr.2023.100514. eCollection 2023 Jun. JTO Clin Res Rep. 2023. PMID: 37304652 Free PMC article.
177 results